{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T05:29:31Z","timestamp":1786339771484,"version":"build-2736575974"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04318-y","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:14:12Z","timestamp":1780582452000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical application of cytokine-induced killer cells in cancer immunotherapy"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0209-3876","authenticated-orcid":false,"given":"Farzaneh","family":"Ghorbani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6284-0855","authenticated-orcid":false,"given":"Hossein","family":"Abbaszadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9169-8245","authenticated-orcid":false,"given":"Yahya","family":"Yahyavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3633-2280","authenticated-orcid":false,"given":"Mehdi","family":"Talebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-857X","authenticated-orcid":false,"given":"Karim","family":"Shamsasenajn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"4318_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12092158","author":"R Ghemrawi","year":"2024","unstructured":"Ghemrawi R, et al. Revolutionizing cancer treatment: recent advances in immunotherapy. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12092158.","journal-title":"Biomedicines"},{"issue":"2","key":"4318_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3892\/ol.2014.2780","volume":"9","author":"XY Yang","year":"2015","unstructured":"Yang XY, Zeng H, Chen FP. Cytokine-induced killer cells: a novel immunotherapy strategy for leukemia. Oncol Lett. 2015;9(2):535\u201341.","journal-title":"Oncol Lett"},{"key":"4318_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cellimm.2013.11.009","volume":"1","author":"X Wang","year":"2014","unstructured":"Wang X, et al. Can the dual-functional capability of CIK cells be used to improve antitumor effects?> Cell Immunol. 2014;1:18\u201322.","journal-title":"Cell Immunol"},{"issue":"8","key":"4318_CR4","doi-asserted-by":"publisher","first-page":"14632","DOI":"10.3390\/ijms150814632","volume":"15","author":"FC Schmeel","year":"2014","unstructured":"Schmeel FC, et al. Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies. Int J Mol Sci. 2014;15(8):14632\u201348.","journal-title":"Int J Mol Sci"},{"key":"4318_CR5","doi-asserted-by":"publisher","DOI":"10.18502\/ijph.v53i8.16277","author":"Z Cheng","year":"2024","unstructured":"Cheng Z, Haowei T, Qun W. Efficacy and safety of autologous cytokine-induced killer (CIK) cellular immunotherapy combined with chemotherapy in non-small-cell carcinoma (NSCLC): a meta-analysis. Iran J Public Health. 2024. https:\/\/doi.org\/10.18502\/ijph.v53i8.16277.","journal-title":"Iran J Public Health"},{"issue":"1","key":"4318_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-024-03869-z","volume":"15","author":"F Ghanbari Sevari","year":"2024","unstructured":"Ghanbari Sevari F, et al. Cytokine-induced killer cells: new insights for therapy of hematologic malignancies. Stem Cell Res Ther. 2024;15(1):254.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"4318_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-84284-5","volume":"15","author":"AS L\u00fcck","year":"2025","unstructured":"L\u00fcck AS, et al. Preclinical evaluation of DC-CIK cells as potentially effective immunotherapy model for the treatment of glioblastoma. Sci Rep. 2025;15(1):734.","journal-title":"Sci Rep"},{"issue":"7","key":"4318_CR8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3109\/14653249.2012.694419","volume":"14","author":"YC Linn","year":"2012","unstructured":"Linn YC, et al. A phase I\/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission. Cytotherapy. 2012;14(7):851\u20139.","journal-title":"Cytotherapy"},{"key":"4318_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/hon.886","author":"P Olioso","year":"2009","unstructured":"Olioso P, et al. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol. 2009. https:\/\/doi.org\/10.1002\/hon.886.","journal-title":"Hematol Oncol"},{"key":"4318_CR10","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1083671","author":"L Xu","year":"2016","unstructured":"Xu L, et al. A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. Oncoimmunology. 2016. https:\/\/doi.org\/10.1080\/2162402X.2015.1083671.","journal-title":"Oncoimmunology"},{"key":"4318_CR11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.4_suppl.518","author":"J-H Lee","year":"2025","unstructured":"Lee J-H, et al. Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: extended follow-up of a randomized controlled trial and post-treatment immune cell profiling. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.518.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4318_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00576-6","volume":"13","author":"J Pu","year":"2024","unstructured":"Pu J, et al. Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma. Experimental Hematology & Oncology. 2024;13(1):105.","journal-title":"Experimental Hematology & Oncology"},{"key":"4318_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1548979","volume":"16","author":"J Dong","year":"2025","unstructured":"Dong J, et al. In-depth analysis of the safety of CAR-T cell therapy for solid tumors. Front Immunol. 2025;16:1548979.","journal-title":"Front Immunol"},{"issue":"6","key":"4318_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2017.1285987","volume":"13","author":"Y Meng","year":"2017","unstructured":"Meng Y, et al. Cell-based immunotherapy with cytokine-induced killer (CIK) cells: from preparation and testing to clinical application. Hum Vaccin Immunother. 2017;13(6):1\u20139.","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"4318_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.humimm.2014.09.021","volume":"76","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, et al. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology. Hum Immunol. 2015;76(5):385\u201391.","journal-title":"Hum Immunol"},{"key":"4318_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/biology12081079","author":"G Tan","year":"2023","unstructured":"Tan G, Spillane KM, Maher J. The role and regulation of the NKG2D\/NKG2D ligand system in cancer. Biology Basel. 2023. https:\/\/doi.org\/10.3390\/biology12081079.","journal-title":"Biology Basel"},{"key":"4318_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092339","author":"AB Jones","year":"2022","unstructured":"Jones AB, et al. Regulation of NKG2D stress ligands and its relevance in cancer progression. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14092339.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4318_CR18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13046-021-01872-3","volume":"40","author":"A Relecom","year":"2021","unstructured":"Relecom A, et al. Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity. J Exp Clin Cancer Res. 2021;40(1):74.","journal-title":"J Exp Clin Cancer Res"},{"key":"4318_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17040566","author":"DH Kim","year":"2025","unstructured":"Kim DH, et al. Cytokine-induced killer cell immunotherapy reduces recurrence in patients with early-stage hepatocellular carcinoma. Cancers. 2025. https:\/\/doi.org\/10.3390\/cancers17040566.","journal-title":"Cancers"},{"key":"4318_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.7150\/jca.2.363","volume":"2","author":"D Sangiolo","year":"2011","unstructured":"Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer. 2011;2:363\u20138.","journal-title":"J Cancer"},{"key":"4318_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1459175","author":"B Rambaldi","year":"2024","unstructured":"Rambaldi B, et al. Genetically modified and unmodified cellular approaches to enhance graft versus leukemia effect, without increasing graft versus host disease: the use of allogeneic cytokine-induced killer cells. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1459175.","journal-title":"Front Immunol"},{"key":"4318_CR22","unstructured":"Wook J. A Brief Note on Cytokine-Induced Killer Cells. 2021."},{"key":"4318_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cytogfr.2017.06.003","volume":"36","author":"E Cappuzzello","year":"2017","unstructured":"Cappuzzello E, et al. Cytokines for the induction of antitumor effectors: the paradigm of Cytokine-Induced Killer (CIK) cells. Cytokine Growth Factor Rev. 2017;36:99\u2013105.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"4318_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/bjh.18469","volume":"200","author":"P Circosta","year":"2023","unstructured":"Circosta P, et al. Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti-leukaemic potential and alloreactivity across major human leukocyte antigen barriers. Br J Haematol. 2023;200(1):64\u20139.","journal-title":"Br J Haematol"},{"key":"4318_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ph13050093","author":"K Mareschi","year":"2020","unstructured":"Mareschi K, et al. Cytokine-induced killer (CIK) cells, in vitro expanded under good manufacturing process (GMP) conditions, remain stable over time after cryopreservation. Pharmaceuticals (Basel). 2020. https:\/\/doi.org\/10.3390\/ph13050093.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"4318_CR26","first-page":"77","volume":"52","author":"E Rettinger","year":"2024","unstructured":"Rettinger E. Cytokine-induced killer cells: a unique platform for adoptive cell immunotherapy after allogeneic hematopoietic stem cell transplantation. Transfus Med Hemother. 2024;52(1):77\u201395.","journal-title":"Transfus Med Hemother"},{"issue":"1","key":"4318_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03591-4","volume":"73","author":"CMY Li","year":"2024","unstructured":"Li CMY, et al. Generation and assessment of cytokine-induced killer cells for the treatment of colorectal cancer liver metastases. Cancer Immunol Immunother. 2024;73(1):6.","journal-title":"Cancer Immunol Immunother"},{"key":"4318_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01218","author":"M Bremm","year":"2019","unstructured":"Bremm M, et al. Improving clinical manufacturing of IL-15 activated cytokine-induced killer (CIK) cells. Front Immunol. 2019. https:\/\/doi.org\/10.3389\/fimmu.2019.01218.","journal-title":"Front Immunol"},{"issue":"1","key":"4318_CR29","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12967-018-1613-5","volume":"16","author":"S Castiglia","year":"2018","unstructured":"Castiglia S, et al. Cytokines induced killer cells produced in good manufacturing practices conditions: identification of the most advantageous and safest expansion method in terms of viability, cellular growth and identity. J Transl Med. 2018;16(1):237.","journal-title":"J Transl Med"},{"key":"4318_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1229540","volume":"14","author":"E Cappuzzello","year":"2023","unstructured":"Cappuzzello E, et al. How can cytokine-induced killer cells overcome CAR-T cell limits. Front Immunol. 2023;14:1229540.","journal-title":"Front Immunol"},{"key":"4318_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1665488","volume":"16","author":"J Qian","year":"2025","unstructured":"Qian J, Liu Y. Recent advances in adoptive cell therapy for cancer immunotherapy. Front Immunol. 2025;16:1665488.","journal-title":"Front Immunol"},{"issue":"6","key":"4318_CR32","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, et al. CD19 CAR-T cells of defined CD4+:CD8\u2009+\u2009composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123\u201338.","journal-title":"J Clin Invest"},{"key":"4318_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2016.2","volume":"1","author":"WY Zhang","year":"2016","unstructured":"Zhang WY, et al. Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report. Signal Transduct Target Ther. 2016;1:16002.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"4318_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","volume":"8","author":"Z Zhao","year":"2018","unstructured":"Zhao Z, et al. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B. 2018;8(4):539\u201351.","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"4318_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/PPO.0000000000000032","volume":"20","author":"S Kakarla","year":"2014","unstructured":"Kakarla S, Gottschalk S. CAR T cells for solid tumors: armed and ready to go? Cancer J. 2014;20(2):151\u20135.","journal-title":"Cancer J"},{"issue":"2","key":"4318_CR36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40259-015-0122-9","volume":"29","author":"V Hillerdal","year":"2015","unstructured":"Hillerdal V, Essand M. Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer. BioDrugs. 2015;29(2):75\u201389.","journal-title":"BioDrugs"},{"key":"4318_CR37","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev-med-061119-015600","volume":"72","author":"A Schmidts","year":"2021","unstructured":"Schmidts A, Wehrli M, Maus MV. Toward better understanding and management of CAR-T cell-associated toxicity. Annu Rev Med. 2021;72:365\u201382.","journal-title":"Annu Rev Med"},{"key":"4318_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1130442","volume":"14","author":"B He","year":"2023","unstructured":"He B, et al. Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies. Front Immunol. 2023;14:1130442.","journal-title":"Front Immunol"},{"key":"4318_CR39","doi-asserted-by":"publisher","first-page":"101407","DOI":"10.1016\/j.smim.2020.101407","volume":"48","author":"J Russick","year":"2020","unstructured":"Russick J, et al. NK cells in the tumor microenvironment: Prognostic and theranostic impact. Recent advances and trends. Semin Immunol. 2020;48:101407.","journal-title":"Semin Immunol"},{"key":"4318_CR40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148649","volume":"138","author":"E Choi","year":"2021","unstructured":"Choi E, et al. Engineering CD70-directed CAR-NK cells for the treatment of hematological and solid malignancies. Blood. 2021;138:1691.","journal-title":"Blood"},{"issue":"9","key":"4318_CR41","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1111\/cas.14993","volume":"112","author":"F Marofi","year":"2021","unstructured":"Marofi F, et al. CAR-NK cell in cancer immunotherapy; a promising frontier. Cancer Sci. 2021;112(9):3427\u201336.","journal-title":"Cancer Sci"},{"key":"4318_CR42","doi-asserted-by":"publisher","DOI":"10.4110\/in.2025.25.e17","author":"B Marr","year":"2025","unstructured":"Marr B, et al. Cytokines in focus: IL-2 and IL-15 in NK adoptive cell cancer immunotherapy. Immune Netw. 2025. https:\/\/doi.org\/10.4110\/in.2025.25.e17.","journal-title":"Immune Netw"},{"issue":"4","key":"4318_CR43","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41423-021-00808-3","volume":"19","author":"F Fang","year":"2022","unstructured":"Fang F, et al. Advances in NK cell production. Cell Mol Immunol. 2022;19(4):460\u201381.","journal-title":"Cell Mol Immunol"},{"key":"4318_CR44","doi-asserted-by":"publisher","DOI":"10.1097\/01.COT.0000754736.41993.ee","volume-title":"CAR NK cell therapy directed against pancreatic cancer","author":"W Froelich","year":"2021","unstructured":"Froelich W. CAR NK cell therapy directed against pancreatic cancer. LWW; 2021."},{"issue":"4","key":"4318_CR45","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2174\/1566523222666211217091724","volume":"22","author":"O Cienfuegos-Jimenez","year":"2022","unstructured":"Cienfuegos-Jimenez O, Vazquez-Garza E, Rojas-Martinez A. CAR-NK cells for cancer therapy: molecular redesign of the innate antineoplastic response. Curr Gene Ther. 2022;22(4):303\u201318.","journal-title":"Curr Gene Ther"},{"key":"4318_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23042387","author":"V Mikhailova","year":"2022","unstructured":"Mikhailova V, et al. Pro- and anti-inflammatory cytokines in the context of NK cell-trophoblast interactions. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23042387.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4318_CR47","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11523-017-0489-2","volume":"12","author":"JJ Mata-Molanes","year":"2017","unstructured":"Mata-Molanes JJ, et al. Cancer Immunotherapy with Cytokine-Induced Killer Cells. Target Oncol. 2017;12(3):289\u201399.","journal-title":"Target Oncol"},{"key":"4318_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.913123","volume":"13","author":"X Wu","year":"2022","unstructured":"Wu X, Schmidt-Wolf IGH. An alternative source for allogeneic CAR T cells with a high safety profile. Front Immunol. 2022;13:913123.","journal-title":"Front Immunol"},{"key":"4318_CR49","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5709104","volume":"2021","author":"Y Yang","year":"2021","unstructured":"Yang Y, et al. Efficacy of enhanced cytokine-induced killer cells as an adjuvant immunotherapy for renal cell carcinoma: Preclinical and clinical studies. J Healthc Eng. 2021;2021:5709104.","journal-title":"J Healthc Eng"},{"issue":"1","key":"4318_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01796-8","volume":"25","author":"F Yun","year":"2025","unstructured":"Yun F, et al. Treatment of refractory non-small cell lung cancer with combined infusion of modified CIK cells and PD1 antibody: safety and efficacy. Clin Exp Med. 2025;25(1):272.","journal-title":"Clin Exp Med"},{"issue":"5","key":"4318_CR51","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/cac2.12539","volume":"44","author":"GR Khosravi","year":"2024","unstructured":"Khosravi GR, et al. Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Commun (Lond). 2024;44(5):521\u201353.","journal-title":"Cancer Commun (Lond)"},{"key":"4318_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13050496","author":"S Ying","year":"2025","unstructured":"Ying S, et al. Harnessing dendritic cell function in hepatocellular carcinoma: advances in immunotherapy and therapeutic strategies. Vaccines. 2025. https:\/\/doi.org\/10.3390\/vaccines13050496.","journal-title":"Vaccines"},{"key":"4318_CR53","doi-asserted-by":"crossref","unstructured":"Ni L. Advances in Human Dendritic Cell-Based Immunotherapy Against Gastrointestinal Cancer. 2022. Volume 13\u20132022.","DOI":"10.3389\/fimmu.2022.887189"},{"issue":"1","key":"4318_CR54","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12935-025-03846-3","volume":"25","author":"K Hadiloo","year":"2025","unstructured":"Hadiloo K, et al. Targeting cancer stem cells with CAR-based immunotherapy: biology, evidence, and future directions. Cancer Cell Int. 2025;25(1):289.","journal-title":"Cancer Cell Int"},{"issue":"8","key":"4318_CR55","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","volume":"31","author":"SJ Bagley","year":"2025","unstructured":"Bagley SJ, et al. Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial. Nat Med. 2025;31(8):2778\u201387.","journal-title":"Nat Med"},{"issue":"1","key":"4318_CR56","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12943-025-02390-y","volume":"24","author":"L Shui","year":"2025","unstructured":"Shui L, et al. Bispecific antibodies: unleashing a new era in oncology treatment. Mol Cancer. 2025;24(1):212.","journal-title":"Mol Cancer"},{"key":"4318_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9070724","volume":"9","author":"G You","year":"2021","unstructured":"You G, et al. Bispecific antibodies: a smart arsenal for cancer immunotherapies. Vaccines. 2021;9:724. https:\/\/doi.org\/10.3390\/vaccines9070724.","journal-title":"Vaccines"},{"issue":"1","key":"4318_CR58","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","volume":"6","author":"S Maleki Vareki","year":"2018","unstructured":"Maleki Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018;6(1):157.","journal-title":"J Immunother Cancer"},{"key":"4318_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00774","volume":"8","author":"X Gao","year":"2017","unstructured":"Gao X, et al. Cytokine-induced killer cells as pharmacological tools for cancer immunotherapy. Front Immunol. 2017;8:774.","journal-title":"Front Immunol"},{"issue":"6b","key":"4318_CR60","first-page":"3997","volume":"28","author":"C Wu","year":"2008","unstructured":"Wu C, et al. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res. 2008;28(6b):3997\u20134002.","journal-title":"Anticancer Res"},{"issue":"4","key":"4318_CR61","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.intimp.2010.12.014","volume":"11","author":"Q Niu","year":"2011","unstructured":"Niu Q, et al. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int Immunopharmacol. 2011;11(4):449\u201356.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"4318_CR62","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s12026-015-8743-0","volume":"64","author":"Y Chen","year":"2016","unstructured":"Chen Y, et al. Tumor MICA status predicts the efficacy of immunotherapy with cytokine-induced killer cells for patients with gastric cancer. Immunol Res. 2016;64(1):251\u20139.","journal-title":"Immunol Res"},{"issue":"9","key":"4318_CR63","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7243","volume":"7","author":"C Dai","year":"2016","unstructured":"Dai C, et al. Implication of combined PD-L1\/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer. Oncotarget. 2016;7(9):10332.","journal-title":"Oncotarget"},{"issue":"2","key":"4318_CR64","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3892\/ol.2013.1376","volume":"6","author":"Y Cui","year":"2013","unstructured":"Cui Y, et al. Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine\u2013induced killer cell therapy in cancer patients. Oncol Lett. 2013;6(2):537\u201341.","journal-title":"Oncol Lett"},{"issue":"12","key":"4318_CR65","doi-asserted-by":"publisher","first-page":"e1226","DOI":"10.1002\/cti2.1226","volume":"9","author":"M Wang","year":"2020","unstructured":"Wang M, et al. Therapeutic strategies to remodel immunologically cold tumors. Clin Transl Immunol. 2020;9(12):e1226.","journal-title":"Clin Transl Immunol"},{"issue":"5","key":"4318_CR66","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00432-014-1864-3","volume":"141","author":"LC Schmeel","year":"2015","unstructured":"Schmeel LC, et al. Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2015;141(5):839\u201349.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"4318_CR67","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1111\/jgh.16584","volume":"39","author":"SK Shin","year":"2024","unstructured":"Shin SK, et al. Immune signature and therapeutic approach of natural killer cell in chronic liver disease and hepatocellular carcinoma. J Gastroenterol Hepatol. 2024;39(9):1717\u201327.","journal-title":"J Gastroenterol Hepatol"},{"key":"4318_CR68","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/CJI.0b013e3182948452","volume":"36","author":"Z Huang","year":"2013","unstructured":"Huang Z, et al. Cytokine-induced Killer Cells in Combination With Transcatheter Arterial Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Patients. J Immunother. 2013;36:287\u201393.","journal-title":"J Immunother"},{"key":"4318_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15205072","author":"Y Tamai","year":"2023","unstructured":"Tamai Y, et al. Combination therapy of immune checkpoint inhibitors with locoregional therapy for hepatocellular carcinoma. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15205072.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"4318_CR70","first-page":"674","volume":"34","author":"W Guo","year":"2014","unstructured":"Guo W, Liu L, Wu D. Dendritic cell-cytokine induced killer cell immunotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: safety and efficacy]. Nan Fang Yi Ke Da Xue Xue Bao. 2014;34(5):674\u20138.","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"issue":"7","key":"4318_CR71","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1053\/j.gastro.2015.02.055","volume":"148","author":"JH Lee","year":"2015","unstructured":"Lee JH, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology. 2015;148(7):1383-e916.","journal-title":"Gastroenterology"},{"issue":"9","key":"4318_CR72","first-page":"689","volume":"96","author":"GZ Pan","year":"2016","unstructured":"Pan GZ, et al. [Effect of CIK on long-term survival in the treatment of HCC after RFA combined TACE]. Zhonghua Yi Xue Za Zhi. 2016;96(9):689\u201392.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"2","key":"4318_CR73","first-page":"160","volume":"36","author":"SQ Long","year":"2016","unstructured":"Long SQ, et al. [Combination of Jianpi Liqi Yiliu Formula with Cytokine-induced Killer Cell Treatment for Advanced Hepatocellular Carcinoma]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2016;36(2):160\u20135.","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi"},{"issue":"2","key":"4318_CR74","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s10875-013-9976-0","volume":"34","author":"X Yu","year":"2014","unstructured":"Yu X, et al. A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. J Clin Immunol. 2014;34(2):194\u2013203.","journal-title":"J Clin Immunol"},{"key":"4318_CR75","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41581-023-00700-5","volume":"19","author":"MM Wolf","year":"2023","unstructured":"Wolf MM, Rathmell WK, de Cubas AA. Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens. Nat Rev Nephrol. 2023;19:440\u201350.","journal-title":"Nat Rev Nephrol"},{"key":"4318_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115322","volume":"163","author":"Z Li","year":"2025","unstructured":"Li Z, et al. Regulatory T cells in renal cell carcinoma: tumor-promoting mechanisms and emerging therapeutic strategies. Int Immunopharmacol. 2025;163:115322.","journal-title":"Int Immunopharmacol"},{"key":"4318_CR77","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1080\/14712598.2024.2418321","volume":"24","author":"N Chaoul","year":"2024","unstructured":"Chaoul N, et al. The future of cellular therapy for the treatment of renal cell carcinoma. Expert Opin Biol Ther. 2024;24:1245\u201359.","journal-title":"Expert Opin Biol Ther"},{"key":"4318_CR78","doi-asserted-by":"publisher","first-page":"8863","DOI":"10.1002\/jcb.28250","volume":"120","author":"S Shirjang","year":"2018","unstructured":"Shirjang S, et al. Promising immunotherapy: highlighting cytokine-induced killer cells. J Cell Biochem. 2018;120:8863\u201383.","journal-title":"J Cell Biochem"},{"issue":"1","key":"4318_CR79","first-page":"67","volume":"31","author":"H Wang","year":"2015","unstructured":"Wang H, et al. [Therapeutic efficacy of dendritic cells pulsed by autologous tumor cell lysate in combination with CIK cells on advanced renal cell carcinoma]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2015;31(1):67\u201371.","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"issue":"2","key":"4318_CR80","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.canlet.2015.03.043","volume":"362","author":"X Zhao","year":"2015","unstructured":"Zhao X, et al. Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma. Cancer Lett. 2015;362(2):192\u20138.","journal-title":"Cancer Lett"},{"key":"4318_CR81","doi-asserted-by":"publisher","first-page":"779248","DOI":"10.3389\/fimmu.2021.779248","volume":"12","author":"L Zhao","year":"2021","unstructured":"Zhao L, et al. High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study. Front Immunol. 2021;12:779248.","journal-title":"Front Immunol"},{"key":"4318_CR82","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/1471-2407-14-251","volume":"14","author":"D Wang","year":"2014","unstructured":"Wang D, et al. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer. 2014;14:251.","journal-title":"BMC Cancer"},{"key":"4318_CR83","doi-asserted-by":"crossref","unstructured":"Zhang L, Pan Y. The Immune Regulatory Role of Cytokine-Induced Killer Cells Treatment on Non-Small Cell Lung Cancer Patients. Lung Cancer - Strategies for Diagnosis and Treatment; 2018.","DOI":"10.5772\/intechopen.78274"},{"key":"4318_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.689132","volume":"12","author":"S Ren","year":"2021","unstructured":"Ren S, et al. The combination of immune checkpoint blockade and angiogenesis inhibitors in the treatment of advanced non-small cell lung cancer. Front Immunol. 2021;12:689132.","journal-title":"Front Immunol"},{"issue":"2","key":"4318_CR85","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.intimp.2015.02.010","volume":"25","author":"P Zhao","year":"2015","unstructured":"Zhao P, et al. Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer. Int Immunopharmacol. 2015;25(2):450\u20136.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"4318_CR86","doi-asserted-by":"publisher","first-page":"10228","DOI":"10.4238\/2015.August.28.6","volume":"14","author":"XP Zhu","year":"2015","unstructured":"Zhu XP, et al. A clinical study evaluating dendritic and cytokine-induced killer cells combined with concurrent radiochemotherapy for stage IIIB non-small cell lung cancer. Genet Mol Res. 2015;14(3):10228\u201335.","journal-title":"Genet Mol Res"},{"key":"4318_CR87","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13014-016-0635-5","volume":"11","author":"L Zhang","year":"2016","unstructured":"Zhang L, et al. Feasibility study of DCs\/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer. Radiat Oncol. 2016;11:60.","journal-title":"Radiat Oncol"},{"issue":"5","key":"4318_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04882-x","volume":"13","author":"S Liu","year":"2022","unstructured":"Liu S, et al. CD4(+) T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer. Cell Death Dis. 2022;13(5):441.","journal-title":"Cell Death Dis"},{"issue":"8","key":"4318_CR89","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.cllc.2022.07.009","volume":"23","author":"L Zhou","year":"2022","unstructured":"Zhou L, et al. A Phase IB trial of autologous cytokine-induced killer cells in combination with Sintilimab, monoclonal antibody against programmed cell death-1, plus chemotherapy in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2022;23(8):709\u201319.","journal-title":"Clin Lung Cancer"},{"issue":"15","key":"4318_CR90","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.7314\/APJCP.2014.15.15.6009","volume":"15","author":"C Jin","year":"2014","unstructured":"Jin C, et al. Impact of cellular immune function on prognosis of lung cancer patients after cytokine-induced killer cell therapy. Asian Pac J Cancer Prev. 2014;15(15):6009\u201314.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"4318_CR91","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s13277-013-1132-1","volume":"35","author":"R Zhong","year":"2014","unstructured":"Zhong R, Han B, Zhong H. A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol. 2014;35(2):987\u201394.","journal-title":"Tumour Biol"},{"issue":"1","key":"4318_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00337-x","volume":"5","author":"L Liu","year":"2020","unstructured":"Liu L, et al. Randomized, multicenter, open-label trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small-cell lung cancer: NCT01631357. Signal Transduct Target Ther. 2020;5(1):244.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"4318_CR93","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/ijc.35422","volume":"157","author":"R Zhong","year":"2025","unstructured":"Zhong R, et al. Efficacy and safety of autologous CIK cell therapy plus Toripalimab with or without chemotherapy in advanced NSCLC: a phase II study. Int J Cancer. 2025;157(3):549\u201358.","journal-title":"Int J Cancer"},{"issue":"1","key":"4318_CR94","first-page":"4346576","volume":"2017","author":"L Procaccio","year":"2017","unstructured":"Procaccio L, et al. Immunotherapy in Gastrointestinal Cancers. Biomed Res Int. 2017;2017(1):4346576.","journal-title":"Biomed Res Int"},{"issue":"6","key":"4318_CR95","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/ijc.28780","volume":"135","author":"K Mimura","year":"2014","unstructured":"Mimura K, et al. Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer. Int J Cancer. 2014;135(6):1390\u20138.","journal-title":"Int J Cancer"},{"key":"4318_CR96","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s12026-015-8743-0","volume":"64","author":"Y Chen","year":"2015","unstructured":"Chen Y, et al. Tumor MICA status predicts the efficacy of immunotherapy with cytokine-induced killer cells for patients with gastric cancer. Immunol Res. 2015;64:251\u20139.","journal-title":"Immunol Res"},{"issue":"6","key":"4318_CR97","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00432-016-2127-2","volume":"142","author":"YC Xu","year":"2016","unstructured":"Xu YC, et al. Chemotherapy with or without autologous cytokine-induced killer cell transfusion as the first-line treatment for stage IV gastrointestinal cancer: a phase II clinical trial. J Cancer Res Clin Oncol. 2016;142(6):1315\u201323.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"4318_CR98","first-page":"228","volume":"15","author":"H Zhao","year":"2016","unstructured":"Zhao H, et al. Autologous cytokine-induced killer cells improves overall survival of metastatic colorectal cancer patients: results from a phase II clinical trial. Clin Colorectal Cancer. 2016;15(3):228\u201335.","journal-title":"Clin Colorectal Cancer"},{"issue":"5","key":"4318_CR99","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00432-016-2330-1","volume":"143","author":"Y Li","year":"2017","unstructured":"Li Y, et al. Preoperative NLR for predicting survival rate after radical resection combined with adjuvant immunotherapy with CIK and postoperative chemotherapy in gastric cancer. J Cancer Res Clin Oncol. 2017;143(5):861\u201371.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4318_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1267369","volume":"14","author":"X Ma","year":"2023","unstructured":"Ma X, et al. Autologous CIK cells combined with chemotherapy as the first-line treatment for locally advanced or metastatic gastric cancer is safe and feasible. Front Immunol. 2023;14:1267369.","journal-title":"Front Immunol"},{"issue":"4","key":"4318_CR101","doi-asserted-by":"publisher","first-page":"e93886","DOI":"10.1371\/journal.pone.0093886","volume":"9","author":"D Gao","year":"2014","unstructured":"Gao D, et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PLoS One. 2014;9(4):e93886.","journal-title":"PLoS One"},{"issue":"6","key":"4318_CR102","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.biopha.2014.07.010","volume":"68","author":"J Zhang","year":"2014","unstructured":"Zhang J, et al. Effects of cytokine-induced killer cell treatment in colorectal cancer patients: a retrospective study. Biomed Pharmacother. 2014;68(6):715\u201320.","journal-title":"Biomed Pharmacother"},{"key":"4318_CR103","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/603871","volume":"2014","author":"H Zhu","year":"2014","unstructured":"Zhu H, et al. Immune response, safety, and survival and quality of life outcomes for advanced colorectal cancer patients treated with dendritic cell vaccine and cytokine-induced killer cell therapy. Biomed Res Int. 2014;2014:603871.","journal-title":"Biomed Res Int"},{"key":"4318_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189353","author":"T Wang","year":"2025","unstructured":"Wang T, et al. Breaking the immune desert: strategies for overcoming the immunological challenges of pancreatic cancer. Biochimica et Biophysica Acta (BBA). 2025. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189353.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"17","key":"4318_CR105","doi-asserted-by":"publisher","first-page":"5066","DOI":"10.1158\/1078-0432.CCR-17-0492","volume":"23","author":"N Jiang","year":"2017","unstructured":"Jiang N, et al. Dendritic Cell\/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. Clin Cancer Res. 2017;23(17):5066\u201373.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"4318_CR106","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00262-014-1566-3","volume":"63","author":"MJ Chung","year":"2014","unstructured":"Chung MJ, et al. Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer. Cancer Immunol Immunother. 2014;63(9):939\u201346.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"4318_CR107","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s12253-018-0541-2","volume":"25","author":"N Li","year":"2019","unstructured":"Li N, et al. Combined Treatment with Autologous CIK Cells, Radiotherapy and Chemotherapy in Advanced Cervical Cancer. Pathol Oncol Res. 2019;25(2):691\u20136.","journal-title":"Pathol Oncol Res"},{"key":"4318_CR108","doi-asserted-by":"publisher","first-page":"707468","DOI":"10.3389\/fimmu.2021.707468","volume":"12","author":"H Cheng","year":"2021","unstructured":"Cheng H, et al. Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer. Front Immunol. 2021;12:707468.","journal-title":"Front Immunol"},{"issue":"6","key":"4318_CR109","doi-asserted-by":"publisher","first-page":"e0130620","DOI":"10.1371\/journal.pone.0130620","volume":"10","author":"Y Li","year":"2015","unstructured":"Li Y, et al. Sequential cytokine-induced killer cell immunotherapy enhances the efficacy of the Gemcitabine plus Cisplatin chemotherapy regimen for metastatic nasopharyngeal carcinoma. PLoS One. 2015;10(6):e0130620.","journal-title":"PLoS One"},{"key":"4318_CR110","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.intimp.2018.04.011","volume":"59","author":"X Huang","year":"2018","unstructured":"Huang X, et al. Rescue of iCIKs transfer from PD-1\/PD-L1 immune inhibition in patients with resectable tongue squamous cell carcinoma (TSCC). Int Immunopharmacol. 2018;59:127\u201333.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"4318_CR111","doi-asserted-by":"publisher","first-page":"898","DOI":"10.4238\/2015.February.2.13","volume":"14","author":"L Yan","year":"2015","unstructured":"Yan L, et al. Efficacy of dendritic cell-cytokine-induced killer immunotherapy plus intensity-modulated radiation therapy in treating elderly patients with esophageal carcinoma. Genet Mol Res. 2015;14(1):898\u2013905.","journal-title":"Genet Mol Res"},{"issue":"1","key":"4318_CR112","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12094-015-1339-2","volume":"18","author":"X Wang","year":"2016","unstructured":"Wang X. Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged\u2009<\u200945). Clin Transl Oncol. 2016;18(1):82\u20137.","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"4318_CR113","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.18632\/oncotarget.12273","volume":"8","author":"DS Kong","year":"2017","unstructured":"Kong DS, et al. Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea. Oncotarget. 2017;8(4):7003\u201313.","journal-title":"Oncotarget"},{"issue":"4","key":"4318_CR114","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000380890","volume":"38","author":"W Li","year":"2015","unstructured":"Li W, et al. Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in metastatic brain tumor patients. Oncol Res Treat. 2015;38(4):160\u20135.","journal-title":"Oncol Res Treat"},{"issue":"8","key":"4318_CR115","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jcyt.2015.04.002","volume":"17","author":"Z Zhang","year":"2015","unstructured":"Zhang Z, et al. Efficacy and safety of cord blood-derived cytokine-induced killer cells in treatment of patients with malignancies. Cytotherapy. 2015;17(8):1130\u20138.","journal-title":"Cytotherapy"},{"issue":"1\u20132","key":"4318_CR116","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000452531","volume":"40","author":"X Li","year":"2016","unstructured":"Li X, et al. Phase II\/III study of radiofrequency ablation combined with cytokine-induced killer cells treating colorectal liver metastases. Cell Physiol Biochem. 2016;40(1\u20132):137\u201345.","journal-title":"Cell Physiol Biochem"},{"key":"4318_CR117","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.12659\/MSM.897657","volume":"22","author":"H Wang","year":"2016","unstructured":"Wang H, et al. Curative Effects of Dendritic Cells Combined with Cytokine-Induced Killer Cells in Patients with Malignant Pericardial Effusion. Med Sci Monit. 2016;22:4159\u201363.","journal-title":"Med Sci Monit"},{"issue":"6","key":"4318_CR118","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1002\/ijc.31531","volume":"143","author":"M Chen","year":"2018","unstructured":"Chen M, et al. Phase Ib\/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed\/refractory alimentary tract cancer. Int J Cancer. 2018;143(6):1530\u201340.","journal-title":"Int J Cancer"},{"issue":"1","key":"4318_CR119","volume":"2012","author":"WMT Braga","year":"2012","unstructured":"Braga WMT, Atanackovic D, Colleoni GWB. The role of regulatory T cells and TH17 cells in multiple myeloma. J Immunol Res. 2012;2012(1):293479.","journal-title":"J Immunol Res"},{"key":"4318_CR120","first-page":"13146","volume":"8 10","author":"X Zhao","year":"2015","unstructured":"Zhao X, et al. Immunomodulatory effect of DC\/CIK combined with chemotherapy in multiple myeloma and the clinical efficacy. Int J Clin Exp Pathol. 2015;8 10:13146\u201355.","journal-title":"Int J Clin Exp Pathol"},{"issue":"6","key":"4318_CR121","first-page":"1633","volume":"23","author":"X Zhao","year":"2015","unstructured":"Zhao X, et al. [Effect of Immunotherapy of Dendritic Cells and Cytokine-Induced Killer Cells Combined with Chemotherapy on Secreting Function of T Lymphocytes in Patients with Multiple Myeloma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015;23(6):1633\u20137.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"2","key":"4318_CR122","first-page":"482","volume":"24","author":"SF Qin","year":"2016","unstructured":"Qin SF, Liu L. Effect and safety of CIK cell infusion on peripheral blood immune cell level in the elderly patients with multiple myeloma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016;24(2):482\u20136.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"26","key":"4318_CR123","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1182\/blood-2009-10-246660","volume":"115","author":"RH Prabhala","year":"2010","unstructured":"Prabhala RH, et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010;115(26):5385\u201392.","journal-title":"Blood"},{"issue":"1","key":"4318_CR124","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s10238-025-01728-6","volume":"25","author":"P Kulig","year":"2025","unstructured":"Kulig P, et al. The role of IL-17-related signaling in myelomagenesis, disease prognosis\/progression, and therapeutic approach-a scoping review. Clin Exp Med. 2025;25(1):194.","journal-title":"Clin Exp Med"},{"key":"4318_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1059715","volume":"10","author":"PS Rana","year":"2022","unstructured":"Rana PS, et al. Targeting TGF-\u03b2 signaling in the multiple myeloma microenvironment: steering CARs and T cells in the right direction. Front Cell Dev Biol. 2022;10:1059715.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"4318_CR126","first-page":"122","volume":"24","author":"X Zhao","year":"2016","unstructured":"Zhao X, et al. [Clinical Efficacy of Dendritic Cells and Cytokine-induced Killer Cells Combined with Chemotherapy for Treating Newly diagnosed Multiple Myeloma and their Effect on Function of CD4(+) CD25(+) T Cells in Peripheral Blood]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016;24(1):122\u20136.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"4318_CR127","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-024-03869-z","author":"F Ghanbari Sevari","year":"2024","unstructured":"Ghanbari Sevari F, et al. Cytokine-induced killer cells: new insights for therapy of hematologic malignancies. Stem Cell Res Ther. 2024. https:\/\/doi.org\/10.1186\/s13287-024-03869-z.","journal-title":"Stem Cell Res Ther"},{"key":"4318_CR128","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.leukres.2016.06.006","volume":"48","author":"Y Luo","year":"2016","unstructured":"Luo Y, et al. Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: a phase I study in patients with relapsed\/refractory hematologic malignancies. Leuk Res. 2016;48:6\u201310.","journal-title":"Leuk Res"},{"issue":"1","key":"4318_CR129","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jcyt.2015.09.012","volume":"18","author":"Y Qiu","year":"2016","unstructured":"Qiu Y, et al. Combination of cytokine-induced killer and dendritic cells pulsed with antigenic \u03b1-1,3-galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy. Cytotherapy. 2016;18(1):91\u20138.","journal-title":"Cytotherapy"},{"issue":"3","key":"4318_CR130","first-page":"738","volume":"24","author":"Y Wu","year":"2016","unstructured":"Wu Y, et al. Clinical Analysis of Autologous Cytokine-induced Killer Cells Combined with IL-2 for Treating of Elderly Patients with B-cell Malignant Lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016;24(3):738\u201343.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"7","key":"4318_CR131","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.bbmt.2019.03.004","volume":"25","author":"M Merker","year":"2019","unstructured":"Merker M, et al. Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions. Biol Blood Marrow Transpl. 2019;25(7):1281\u201392.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"4318_CR132","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.bbmt.2019.03.027","volume":"25","author":"R Narayan","year":"2019","unstructured":"Narayan R, et al. Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms. Biol Blood Marrow Transpl. 2019;25(7):1293\u2013303.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"4318_CR133","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12185-014-1618-7","volume":"100","author":"H Wang","year":"2014","unstructured":"Wang H, et al. Homing of cytokine-induced killer cells during the treatment of acute promyelocytic leukemia. Int J Hematol. 2014;100(2):165\u201370.","journal-title":"Int J Hematol"},{"key":"4318_CR134","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7243","author":"C Dai","year":"2016","unstructured":"Dai C, et al. Implication of combined PD-L1\/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer. Oncotarget. 2016. https:\/\/doi.org\/10.18632\/oncotarget.7243.","journal-title":"Oncotarget"},{"issue":"12","key":"4318_CR135","doi-asserted-by":"publisher","first-page":"9291","DOI":"10.1002\/jcp.29827","volume":"235","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Schmidt-Wolf IGH. Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy. J Cell Physiol. 2020;235(12):9291\u2013303.","journal-title":"J Cell Physiol"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04318-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04318-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04318-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T05:03:01Z","timestamp":1786338181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04318-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":135,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4318"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04318-y","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No new human or animal subjects were involved, and no original clinical data were generated by the authors.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review does not contain any individual person\u2019s data in any form.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"279"}}